Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Orr

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 2, 2013
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsSusan L Baldwin, Lance K Ching, Samuel O Pine, et al.
The Journal of Infectious Diseases|August 15, 2012
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatmentRhea N Coler, Sylvie Bertholet, Samuel O Pine, et al.
Vaccine|November 7, 2015
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacyMark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2016
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist AdjuvantsAnthony L Desbien, Natasha Dubois Cauwelaert, Steven J Reed, et al.
European Journal of Immunology|November 5, 2014
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γAnthony L Desbien, Steven J Reed, Hilton R Bailor, et al.
The Journal of Clinical Investigation|July 13, 2018
αv Integrins regulate germinal center B cell responses through noncanonical autophagyFiona Raso, Sara Sagadiev, Samuel Du, et al.
NPJ Vaccines|September 28, 2020
Preclinical optimization of an enterotoxigenic <i>Escherichia coli</i> adjuvanted subunit vaccine using response surface design of experimentsDavid Poncet, Catherine Hessler, Hong Liang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisMark T Orr, Christopher B Fox, Susan L Baldwin, et al.
European Journal of Immunology|May 30, 2013
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantMark T Orr, Malcolm S Duthie, Hillarie Plessner Windish, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 3, 2014
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilizationMark T Orr, Ryan M Kramer, Lucien Barnes, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Journal of Immunology (Baltimore, Md. : 1950)|August 2, 2013
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsSusan L Baldwin, Lance K Ching, Samuel O Pine, et al.
The Journal of Infectious Diseases|August 15, 2012
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatmentRhea N Coler, Sylvie Bertholet, Samuel O Pine, et al.
Vaccine|November 7, 2015
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacyMark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2016
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist AdjuvantsAnthony L Desbien, Natasha Dubois Cauwelaert, Steven J Reed, et al.
European Journal of Immunology|November 5, 2014
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γAnthony L Desbien, Steven J Reed, Hilton R Bailor, et al.
The Journal of Clinical Investigation|July 13, 2018
αv Integrins regulate germinal center B cell responses through noncanonical autophagyFiona Raso, Sara Sagadiev, Samuel Du, et al.
NPJ Vaccines|September 28, 2020
Preclinical optimization of an enterotoxigenic <i>Escherichia coli</i> adjuvanted subunit vaccine using response surface design of experimentsDavid Poncet, Catherine Hessler, Hong Liang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisMark T Orr, Christopher B Fox, Susan L Baldwin, et al.
European Journal of Immunology|May 30, 2013
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantMark T Orr, Malcolm S Duthie, Hillarie Plessner Windish, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 3, 2014
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilizationMark T Orr, Ryan M Kramer, Lucien Barnes, et al.
Pageof 5